Connection

MARGARET GOODELL to Cell Line, Tumor

This is a "connection" page, showing publications MARGARET GOODELL has written about Cell Line, Tumor.
Connection Strength

0.369
  1. SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells. Elife. 2024 Jun 18; 12.
    View in: PubMed
    Score: 0.130
  2. Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018 09 10; 34(3):499-512.e9.
    View in: PubMed
    Score: 0.087
  3. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia. Blood. 2016 08 18; 128(7):971-81.
    View in: PubMed
    Score: 0.075
  4. Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL. Cancer Res. 2021 10 01; 81(19):5033-5046.
    View in: PubMed
    Score: 0.027
  5. A combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells. Nat Commun. 2020 02 06; 11(1):740.
    View in: PubMed
    Score: 0.024
  6. Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood. 2007 Mar 01; 109(5):1897-907.
    View in: PubMed
    Score: 0.010
  7. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
    View in: PubMed
    Score: 0.008
  8. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res. 2004 Mar; 28(3):295-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.